click enter text
merck report financi result morn compani
broadli beat revenu ep rais guidanc
remain bullish bodi report full analysi
remind hold one pipelin unplug
confer call manag thursday et
inform stock cover see global
 april issu monthli controversi report
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
tuesday open merck
report result us/consensu revenu ep
rais revenu ep guidanc consensu alreadi fall within new rang
saw share price rise
overal impress deliv good result beat revenu ep rais
revenu ep guidanc apart financi result rel quiet quarter major
updat keytruda in-lin expect gardasil slightli ahead ex-u perform
substanti partli driven china highlight prior research key growth driver
seem perform might impact variou smaller one-off item talk
recent week smaller headwind end pose risk ep confer call
content lite major new disclosur continu claim pipelin good ever
disconnect rel investor percept eye mani includ us late-stag pipelin
thin rel spend roughli interest see say newly-
announc june investor meet topic meantim mrk depend keytruda
grow ever-high brand set deliv continu strong growth addit sourc long-term
option upsid beyond high estim analyst alreadi forecast alon enough
carri stori view ye creat singl product concentr risk may concern due
time loe occur decad yet earli overli concern realiti
fact driver growth gardasil lynparza product
remind hold one pipelin unplug confer call manag
thursday et
inform stock cover see global pharmaceut april issu monthli
term sale ep exhibit
revenu report sale well estim consensu
non-gaap ep strong revenu one-tim tax benefit translat ep
estim consensu
keytruda sale keytruda sale came roughli in-lin consensu estim
januvia/janumet sale januvia/janumet sale came estim slightli
consensu ex-u util compens continu net price declin us
gardasil sale gardasil sale came estim ahead consensu
purchas time drove weak us sale
page
revenu guid vs prior
pipelin new materi news disclos
revenu increas ep increas
revenu estim chang ep estim chang
depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate remain repres above/below peer
price target new price target vs prior repres unchang
multipl new slightli higher ep estim
gener prepar remark note
one strongest quarter recent histori china sale account
recent background research relev keytruda see slide
lung cancer trial watch azn poseidon neptun
prepar remark management note recent post keytruda trial ct gov
posit natur
 china opportun seek nrdl list sure get remain excit
growth potenti
 keytruda lung eu lung repres sale outsid us access still improv
lung expect
 averag net price eu vs us think potenti impact disclos
page
 china market keytruda think coupl hundr thousand patient
elig keytruda
 keytruda monotherapi opportun base stage excit opportun
smaller subset stage metastat set patient want monotherapi without
 one-tim factor impact perform advers look underli demand
remain solid fluctuat quarter quarter due purchas etc squamou lung market share
outsid lung see rcc signific opportun futur growth excit
 outsid us japan china eu remain big growth driver
 lung trend us max share like peak exclud driver mutat patient market
share low non-sq nsclc get pretti much pt
biggest futur inroad lay
 inventori swing alway slight movement brand size
 long-term outlook keytruda china potenti price competit believ oncolog data
driven diseas wall data differenti market place local player china
dont lung approv
 sale indic us lung mrl bladder high
 data year possibl ye driven dsmb cant speak data
declin us repres time purchas offset strong underli demand
follow pfe
background research product see recent slide deck present
slide race pneumococc vaccin
 bring tabl vs market incumb say inexperienc
pneumovax conjug vaccin develop
perlmutt first stint import contributor doubt
 eventu acip recommend expect opportun ped adult
page
 livestock perform weaker end overal ah market expect grow
saw impact cold weather flood per se expect market growth full year
 expens trend time margin expansion/evolut continu guid meaning op margin
expans time continu see grow next coupl year probabl faster sale
moder
 current plan activ smaller deal last year balanc sheet look
everyth focus bolt-on realli asset seem fulli valu market recoveri
 futur role primari care compani given mix shift portfolio say
go compani total focus one particular area follow scienc primari
care product specialti product market develop
 ultim impact part goe impact continu
say best approach earli day still say might implement
 comment immunedesign deal principl asset adjuv newer vaccin lentiviru
 china product blockbust see number product big potenti keytruda
 china perform overal given shift innov product see impact new
measur portfolio innov product set well near- long-term
 combin potenti come truvada-lik regimen quit optimist
quit strong respons moa long-term seek combin program
simplifi dose regimen need much larger studi
 elabor data prior clinic trial support safeti product
underli logic moa contribut hypersensit syndrom tie multipl diseas first
set chronic cough look other
page
exhibit show compani report actual result vs estim consensu
exhibit merck result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit merck guidanc vs wr estim old new
page
oldnewoldnewtot incl incl marginin-lin bpssg amanag tightlymanag grow faster sale faster expenseshigh low- mid-singl digit rate low- mid-singl digit rate guidancewr estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement pharma anim oper incom income/ expens incom outstand margin total margin incom oper
page
product revenu daili total isentress remicad simponi zepati biosimilar viral vaccin proquad varivax gardasil januvia dulera allergi women bridion keytruda onc pain product earli phase revenu incl lynparza total
exhibit wr merck balanc sheet cash flow statement
page
flow statement incom incom chang asset flow oper activ secur subsidiari sale secur subsidiari flow invest activ chang short-term treasuri paid flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr paid-in comprehens treasuri stock merck sharehold sharehold liabil sharehold
